keyword
MENU ▼
Read by QxMD icon Read
search

Bupropione

keyword
https://www.readbyqxmd.com/read/29998114/association-of-novel-alx4-gene-polymorphisms-with-antidepressant-treatment-response-findings-from-the-co-med-trial
#1
Bharathi S Gadad, Prithvi Raj, Manish K Jha, Thomas Carmody, Igor Dozmorov, Taryn L Mayes, Edward K Wakeland, Madhukar H Trivedi
Genome-wide association studies (GWAS) were conducted in participants of the CO-MED (Combining Medications to Enhance Depression Outcomes) trial, a randomized, 3-treatment arm clinical trial of major depressive disorder (MDD) designed to identify markers of differential treatment outcome (response and remission). The QIDS-SR (Quick Inventory of Depressive Symptomatology, Self-Reported version) was used to measure response at week 6 (QIDS-SR ≤5) and remission at week 12 (QIDS-SR ≤6 and ≤8 at the last two study visits)...
June 2018: Molecular Neuropsychiatry
https://www.readbyqxmd.com/read/29995725/female-sexual-dysfunction-and-the-placebo-effect-a-meta-analysis
#2
James M Weinberger, Justin Houman, Ashley T Caron, Devin N Patel, Avi S Baskin, A Lenore Ackerman, Karyn S Eilber, Jennifer T Anger
OBJECTIVE: To quantify the placebo effect of various pharmacologic modalities including neuromodulators, hormonal agents, and onabotulinum toxin A for female sexual dysfunction. DATA SOURCES: Using Meta-analyses Of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE, ClinicalTrials.gov, and the Cochrane Review databases. METHODS OF STUDY SELECTION: Eleven search terms, "female sexual dysfunction" "treatment" in combination with "hypoactive sexual desire," "arousal disorder," "sexual pain disorder," "genitourinary syndrome of menopause," "orgasmic disorder," "vulvovaginal atrophy," "vaginismus," "vaginal atrophy," "vulvodynia," and "vestibulitis," were used...
July 10, 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29993319/combination-therapies-for-obesity
#3
Michael Camilleri, Andres Acosta
The objective of this review is to examine advances in the development of combination therapies for the treatment of obesity beyond diet or lifestyle interventions. Experimental combination pharmacotherapies include combinations of pramlintide and phentermine as well as amylin and bupropion-naltrexone. Incretin and pancreatic hormones generally inhibit upper gastrointestinal motor functions, and combinations showing efficacy in obesity are coadministration of glucagon-like peptide-1 (GLP-1) with glucagon, a unimolecular dual incretin of PEGylated GLP-1/GIP coagonist, the combination of GLP-1 and PYY3-36 , and, in proof of concept studies, combined infusions of GLP-1, peptide YY, and oxyntomodulin...
July 11, 2018: Metabolic Syndrome and related Disorders
https://www.readbyqxmd.com/read/29989445/second-generation-anti-depressants-and-risk-of-new-onset-seizures-in-the-elderly
#4
Yaron Finkelstein, Erin M Macdonald, Ping Li, Muhammad M Mamdani, Tara Gomes, David N Juurlink
BACKGROUND: Anti-depressants are among the most widely-prescribed medications. It is unknown whether the risk of seizure during therapeutic use differs by drug. We ranked the seizure risk of popular anti-depressants. METHODS: We conducted a population-based case-control study between April 2002 and March 2015 in Ontario, Canada. Cases were Ontario residents aged ≥65 years hospitalized for a first-ever seizure within 60 d of filling a prescription for one of nine second-generation anti-depressants, each dispensed more than 1 million times (range: 1,196,810 [fluvoxamine] to 19,849,930 [citalopram]) during the study period...
July 10, 2018: Clinical Toxicology
https://www.readbyqxmd.com/read/29973132/randomized-double-blind-parallel-group-placebo-controlled-trial-of-bupropion-as-treatment-for-methadone-emergent-sexual-dysfunction-in-men
#5
Anne Yee, Huai Seng Loh, Teng Aik Ong, Chong Guan Ng, Ahmad Hatim Sulaiman
Methadone is largely recognized as an effective treatment for opiate-dependent patients; however, it causes reduced brain dopaminergic action resulting in significant sexual dysfunction. Bupropion is a dopamine reuptake inhibitor which can potentially improve erectile function among male patients on methadone (MMT). This is a phase II, randomized, double-blind, parallel-group, placebo-controlled trial, involving 80 MMT male patients (73.4%) with mean age of 42.83 years ±9.68. These MMT male patients were randomly assigned into two groups to receive bupropion and placebo, respectively...
July 1, 2018: American Journal of Men's Health
https://www.readbyqxmd.com/read/29961917/molecular-basis-of-atypicality-of-bupropion-inferred-from-its-receptor-engagement-in-nervous-system-tissues
#6
Eric J Kim, Klara Felsovalyi, Lauren M Young, Sergey V Shmelkov, Michael F Grunebaum, Timothy Cardozo
Despite decades of clinical use and research, the mechanism of action (MOA) of antidepressant medications remains poorly understood. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the most commonly prescribed antidepressants-atypical antidepressants such as bupropion have also proven effective, while exhibiting a divergent clinical phenotype. The difference in phenotypic profiles presumably lies in the differences among the MOAs of SSRIs/SNRIs and bupropion...
July 1, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29955558/role-of-antidepressants-in-the-treatment-of-adults-with-anorexia-nervosa
#7
REVIEW
Marketa Marvanova, Kirstin Gramith
Introduction: Anorexia nervosa (AN) is a severe psychiatric disorder that is difficult to treat and is associated with frequent relapses and high mortality rates. Psychiatric symptomatology (eg, depression, anxiety, obsessive-compulsive disorder/behaviors) are common comorbidities. This review provides current information about safety and efficacy of antidepressant therapy for management of AN in adults. Methods: A literature review of randomized controlled trials, open-label studies, and case reports with adults or adults/adolescents was conducted...
May 2018: The mental health clinician
https://www.readbyqxmd.com/read/29955550/review-of-pharmacotherapy-for-smoking-cessation-in-patients-with-schizophrenia
#8
REVIEW
Avery E Shawen, Shannon J Drayton
Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia. Eighteen studies were found and included in the review. Overall, nicotine replacement therapy, bupropion, and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use...
March 2018: The mental health clinician
https://www.readbyqxmd.com/read/29943503/the-influence-of-selective-a1-and-a2a-receptor-antagonists-on-the-antidepressant-like-activity-of-moclobemide-venlafaxine-and-bupropion-in-mice
#9
Karolina Bogatko, Ewa Poleszak, Aleksandra Szopa, Elżbieta Wyska, Piotr Wlaź, Katarzyna Świąder, Aleksandra Wlaź, Urszula Doboszewska, Karol Rojek, Anna Serefko
OBJECTIVE: The main goal of our study was to investigate whether a selective antagonism of the adenosine A1 or A2A receptors is able to enhance the antidepressant activity of commonly prescribed drugs. MATERIALS AND METHODS: All experiments were carried out on male Albino Swiss mice. The forced swim test and the tail suspension test were used to evaluate the antidepressant-like potential. Drug concentrations in animals' serum and brains were measured by high-performance liquid chromatography...
June 25, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29936939/removed-pb-16-restingstate-alterations-under-antidepressant-treatment-and-the-relation-to-sexual-side-effects-comparison-of-bupropion-paroxetine-and-placebo
#10
C Metzger, B Abler, G Grön, M Walter, H Graf
This article has been removed: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been removed at the request of the Publisher, as the authors did not give permission for the abstract to be published.
October 2017: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://www.readbyqxmd.com/read/29936730/potential-role-of-bupropion-sustained-release-for-cancer-related-fatigue-a-double-blind-placebo-controlled-study
#11
Farzaneh Ashrafi, Sarah Mousavi, Mohammad Karimi
Background: Cancer-related fatigue (CRF) is very common and can be experienced at all stages of disease and in survivors. CRF causes patients more distress than pain or nausea and vomiting. Different pharmacologic interventions have been evaluated for the management of CRF. The purpose of this study was to determine the efficacy of bupropion sustained release (SR) as a treatment for fatigue in patients with cancer. Methods: In this randomized, double-blind, placebo-controlled trial, patients with fatigue due to cancer were randomly assigned to either 150mg daily of bupropion SR or matching placebo...
June 25, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29923970/vortioxetine-overdose-in-a-suicidal-attempt-a-case-report
#12
Mario Gennaro Mazza, Aurora Rossetti, Eugenia Rossana Botti, Massimo Clerici
RATIONALE: Vortioxetine is a new multimodal antidepressant approved by the Food and Drug Administration for the treatment of Major Depressive Disorder and recently introduced in Europe. While antidepressant properties of vortioxetine and its tolerability have been demonstrated by preclinical and clinical studies data on the safety of vortioxetine after overdose are still lacking. PATIENT CONCERNS: A 50-year-old Caucasian man presenting a severe depressive episode that in a suicide attempt he took vortioxetine at 250 mg...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29920885/comprehensive-comparison-of-monotherapies-for-psychiatric-hospitalization-risk-in-bipolar-disorders
#13
Anastasiya Nestsiarovich, Aurélien J Mazurie, Nathaniel G Hurwitz, Berit Kerner, Stuart J Nelson, Annette S Crisanti, Mauricio Tohen, Ronald L Krall, Douglas J Perkins, Christophe G Lambert
OBJECTIVES: This study compared 29 drugs for risk of psychiatric hospitalization in bipolar disorders, addressing the evidence gap on the >50 drugs used by US patients for treatment. METHODS: The Truven Health Analytics MarketScan® database was used to identify 190 894 individuals with bipolar or schizoaffective disorder who filled a prescription for one of 29 drugs of interest: lithium, first- or second-generation antipsychotics, mood-stabilizing anticonvulsants, and antidepressants...
June 19, 2018: Bipolar Disorders
https://www.readbyqxmd.com/read/29908433/a-retrospective-analysis-of-the-association-between-providing-nicotine-replacement-therapy-at-admission-and-motivation-to-quit-and-nicotine-withdrawal-symptoms-during-an-inpatient-psychiatric-hospitalization
#14
Chizimuzo T C Okoli, Yazan D Al-Mrayat, Charles I Shelton, Milan Khara
BACKGROUND: Psychiatric patients have high tobacco use prevalence, dependence, and withdrawal severity. A tobacco-free psychiatric hospitalization necessitates the management of nicotine withdrawal (NW) for tobacco using patients. NW management often requires the provision of approved nicotine replacement therapy (NRT) to patients, which may also motivate tobacco users towards cessation. However, few studies have examined the associations between providing NRT, motivation to quit, and NW among psychiatric patients...
June 7, 2018: Addictive Behaviors
https://www.readbyqxmd.com/read/29901567/association-of-antidepressant-use-with-drug-related-extrapyramidal-symptoms-a-pharmacoepidemiological-study
#15
Michael Y Guo, Mahyar Etminan, Ric M Procyshyn, David D Kim, Ali Samii, Abbas Kezouh, Bruce C Carleton
BACKGROUND: Antidepressants are one of the most prescribed classes of medications. A number of case reports have linked these drugs to extrapyramidal symptoms (EPSs), but no large epidemiologic study to date has examined this association. We sought to quantify the association of EPSs with different antidepressants by undertaking a large pharmacoepidemiologic study. METHODS: A nested case-control study was conducted using a large health claims database in the United States from June 2006 to December 2015...
June 12, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29897361/occurrence-and-source-analysis-of-selected-antidepressants-and-their-metabolites-in-municipal-wastewater-and-receiving-surface-water
#16
Luo-Dan Ma, Jian Li, Jia-Jun Li, Min Liu, Dong-Zhi Yan, Wen-Yan Shi, Gang Xu
Seven commonly utilized antidepressants (amitriptyline, fluoxetine, sertraline, citalopram, paroxetine, venlafaxine, and bupropion) and three of their metabolites were detected in four wastewater treatment plants (WWTPs) and corresponding receiving waters including the mainstream and three of the tributaries of Huangpu River, Shanghai. The concentration levels of selected antidepressants in wastewater and receiving water were both at ng L-1 level, but those antidepressants that were found in wastewater were typically in a range of one and even two orders of magnitude higher than those that were present in the receiving water except for the concentration levels of paroxetine, norfluoxetine, and nortriptyline...
June 13, 2018: Environmental Science. Processes & Impacts
https://www.readbyqxmd.com/read/29890171/weight-loss-strategies-for-treatment-of-obesity-lifestyle-management-and-pharmacotherapy
#17
REVIEW
Robert F Kushner
Obesity is one of the most serious and prevalent non-communicable diseases of the twenty-first century. It is also a patient-centered condition in which affected individuals seek treatment through a variety of commercial, medical and surgical approaches. Considering obesity as a chronic medical disease state helps to frame the concept of using a three-stepped intensification of care approach to weight management. As a foundation, all patients should be counseled on evidence-based lifestyle approaches that include diet, physical activity and behavior change therapies...
June 8, 2018: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/29881267/socioeconomic-inequality-in-the-use-of-prescription-medications-for-smoking-cessation-among-patients-with-copd-a-nationwide-study
#18
Sandra Søgaard Tøttenborg, Alice Jessie Clark, Reimar Wernich Thomsen, Søren Paaske Johnsen, Peter Lange
Background: Bupropion and varenicline can substantially improve the chances of smoking cessation in patients with COPD, but are unsubsidized and relatively costly. We examined overall use and socioeconomic patterns of use among patients with COPD. Patients and methods: We identified 4,741 COPD patients reporting to be smokers at their first contact for COPD during 2008-2012 in the Danish register of COPD, which covers all pulmonary outpatient clinics in Denmark...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29873957/risk-of-diabetes-hospitalization-or-diabetes-drug-intensification-in-patients-with-depression-and-diabetes-using-second-generation-antipsychotics-compared-to-other-depression-therapies
#19
Shan Xing, Shiyun Kim, Glen T Schumock, Daniel R Touchette, Gregory S Calip, Alex D Leow, Todd A Lee
Objective: Use of second-generation antipsychotics (SGAs) for treatment of depression has increased, and patients with depression and comorbid diabetes or cardiovascular disease are more likely to use SGAs than those without these conditions. We compared SGA and non-SGA depression pharmacotherapies on the risk of diabetes hospitalization or treatment intensification in adults with depression and preexisting diabetes. Methods: This was a retrospective cohort study of US commercially insured adults (2009-2015 Truven MarketScan Commercial Claims and Encounters Database) aged 18-64 years old with type 2 diabetes mellitus and unipolar depression previously treated with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor...
May 10, 2018: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/29870591/amenamevir-studies-of-potential-cyp2c8-and-cyp2b6-mediated-pharmacokinetic-interactions-with-montelukast-and-bupropion-in-healthy-volunteers
#20
Jeremy Dennison, Adeep Puri, Steven Warrington, Takamasa Endo, Temitope Adeloye, Atholl Johnston
Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8.  We conducted 2 studies, 1 using montelukast as a probe to assess CYP2C8 and the other bupropion to assess CYP2B6.  The montelukast study examined the effect of amenamevir on the pharmacokinetics of montelukast in 24 healthy men: each subject received montelukast 10 mg alone, followed by montelukast 10 mg with amenamevir 400 mg, or vice versa after a washout period.  In the bupropion study, 24 subjects received a single dose of 150 mg bupropion on days 1, 15, 22, and 29, and repeated once-daily doses of 400 mg amenamevir on days 6-15...
June 5, 2018: Clinical Pharmacology in Drug Development
keyword
keyword
109274
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"